The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

(2018) David Ghez et al.   BLOOD

Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies

(2018) Benjamin F. Tillman et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk

(2017) Martijn HA van Attekum et al.   HAEMATOLOGICA

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk

(2017) Martijn HA van Attekum et al.   HAEMATOLOGICA

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

(2017) Iris de Weerdt et al.   HAEMATOLOGICA

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

(2017) Jeffrey A Jones et al.   Lancet Haematology

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

(2016) A. R. Mato et al.   BLOOD

AtypicalPneumocystis jiroveciipneumonia in previously untreated patients with CLL on single-agent ibrutinib

(2016) Inhye E. Ahn et al.   BLOOD

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia

(2016) Jennifer R. Brown   SEMINARS IN ONCOLOGY

Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment

(2015) Michael Hallek   AMERICAN JOURNAL OF HEMATOLOGY

Idelalisib-associated Enterocolitis

(2015) Christine Y. Louie et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Idelalisib-associated Colitis

(2015) Anna-Sophie Weidner et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

(2015) J. C. Byrd et al.   BLOOD

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

(2015) A. Osterborg et al.   HAEMATOLOGICA

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

(2015) K Balakrishnan et al.   LEUKEMIA

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival

(2015) Valentina Trimarco et al.   Oncotarget

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

(2015) A. Osterborg et al.   HAEMATOLOGICA

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

(2015) Kami J. Maddocks et al.   JAMA Oncology

The future of autologous stem cell transplantation in myeloma

(2014) F. van Rhee et al.   BLOOD

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

(2013) David G. Winkler et al.   CHEMISTRY & BIOLOGY

Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers

(2013) T. Shanafelt   Hematology-American Society of Hematology Education Program

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

(2012) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

(2012) AnnaMaria Nosari   Mediterranean Journal of Hematology and Infectious Diseases

Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia

(2011) X.-J. Yan et al.   BLOOD

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

(2011) Michael C. Schmid et al.   CANCER CELL

Update on Therapy of Chronic Lymphocytic Leukemia

(2011) John G. Gribben et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K/p110  is a novel therapeutic target in multiple myeloma

(2010) H. Ikeda et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD